ArticleJournal of neurochemistry2026
Validation of TRPA1 and TRPV1 Antibodies for Expression Detection in Mammalian Cells and Tissues.
Article in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular target for neuroinflammation and pain management: transient receptor potential vanilloid 1.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antibodies are key reagents in cell biology and biochemistry research. The validation of their performance, in terms of sensitivity and specificity, is essential for their correct application. TRPV1 and TRPA1 are non-selective cation channels expressed in primary sensory neurons, where they mediate the detection of diverse physical and chemical stimuli. They play key roles in nociception and inflammatory processes, making them important targets for mechanistic and therapeutic pain studies, highlighting the need for reliable evaluation of their expression. The detection and quantification of TRPV1 and TRPA1 protein expression is commonly carried out using antibody-based techniques, such as immunohistochemistry and western blotting. However, as with other TRP channels and membrane proteins, antibody performance is frequently suboptimal, leading to potential misinterpretation of results and erroneous conclusions. In this study, we systematically evaluated the performance of five TRPV1 and seven TRPA1 commercial antibodies in immunocytochemistry, immunohistochemistry, and western blotting, using both heterologous and native expression systems. We identified two TRPV1 antibodies that consistently yielded robust and specific signals across all techniques and expression models tested; their specificity was validated using a TRPV1 KO mouse. For the remaining antibodies, we provide guidance to facilitate the selection of the most appropriate reagent according to the experimental approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.